Condensed Consolidated Statement of Changes in Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Noncontrolling Interest [Member]	Total
Beginning balance at Dec. 31, 2021	$ 2,419	$ 86	$ 198,071	$ (138,910)		$ 17,752	$ 79,418
Beginning balance, shares at Dec. 31, 2021	1,113,919	86,367,845
Dividends declared - Series B Convertible Preferred Stock	$ 135			(135)
Dividends declared - Series B Convertible Preferred Stock, shares	45,031
Impact of subsidiary equity transactions			12			229	241
Stock-based compensation - PAVmed Inc.			2,726				2,726
Stock-based compensation - majority-owned subsidiaries						7,094	7,094
Net Loss				(42,397)		(6,337)	(48,734)
Vest - restricted stock awards			(1)				(1)
Vest - restricted stock awards, shares		541,666
Purchase - Employee Stock Purchase Plan			217				217
Purchase - Employee Stock Purchase Plan, shares		194,240
Treasury stock					(548)		(548)
Treasury stock, shares		(380,544)
Exercise - stock options		$ 1	302				303
Exercise - stock options, shares		299,999
Exercise - stock options of majority-owned subsidiary						688	688
Exercise - Series Z warrants
Exercise - Series Z warrants, shares		5
Ending balance at Jun. 30, 2022	$ 2,554	$ 87	201,327	(181,442)	(548)	19,426	41,404
Ending balance, shares at Jun. 30, 2022	1,158,950	87,023,211
Beginning balance at Mar. 31, 2022	$ 2,486	$ 87	199,719	(155,849)	(512)	18,802	64,733
Beginning balance, shares at Mar. 31, 2022	1,136,210	86,911,646
Dividends declared - Series B Convertible Preferred Stock	$ 68			(68)
Dividends declared - Series B Convertible Preferred Stock, shares	22,740
Impact of subsidiary equity transactions			99			142	241
Stock-based compensation - PAVmed Inc.			1,449				1,449
Stock-based compensation - majority-owned subsidiaries						3,557	3,557
Net Loss				(25,525)		(3,576)	(29,101)
Vest - restricted stock awards			(1)				(1)
Vest - restricted stock awards, shares		75,000
Treasury stock					(36)		(36)
Treasury stock, shares		(25,935)
Exercise - stock options			61				61
Exercise - stock options, shares		62,500
Exercise - stock options of majority-owned subsidiary						501	501
Ending balance at Jun. 30, 2022	$ 2,554	$ 87	201,327	(181,442)	(548)	19,426	41,404
Ending balance, shares at Jun. 30, 2022	1,158,950	87,023,211
Beginning balance at Dec. 31, 2022	$ 2,695	$ 95	216,106	(228,169)	(408)	20,615	10,934
Beginning balance, shares at Dec. 31, 2022	1,205,759	94,510,537
Ending balance at Mar. 31, 2023	$ 2,767	$ 101	221,247	(246,172)		32,861	10,804
Ending balance, shares at Mar. 31, 2023	1,229,887	100,596,406
Beginning balance at Dec. 31, 2022	$ 2,695	$ 95	216,106	(228,169)	(408)	20,615	10,934
Beginning balance, shares at Dec. 31, 2022	1,205,759	94,510,537
Dividends declared - Series B Convertible Preferred Stock	$ 146			(146)
Dividends declared - Series B Convertible Preferred Stock, shares	48,738
Issue common stock - PAVM ATM Facility		$ 2	1,164				1,166
Issue common stock - PAVM ATM Facility, shares		2,330,747
Impact of subsidiary equity transactions			1,332			(1,332)
Issuance - vendor service agreement		$ 2	600			147	749
Issuance vendor service agreement, shares		1,500,000
Stock-based compensation - PAVmed Inc.			2,288				2,288
Stock-based compensation - majority-owned subsidiaries			646			3,992	4,638
Net Loss				(32,468)		(7,638)	(40,106)
Vest - restricted stock awards
Vest - restricted stock awards, shares		100,000
Conversions - Senior Secured Convertible Note		$ 10	4,411				4,421
Conversions - Senior Secured Convertible Note, shares		9,523,481
Purchase - Employee Stock Purchase Plan			122		60		182
Purchase - Employee Stock Purchase Plan, shares		384,383
Purchase - majority-owned subsidiary common stock - Employee Stock Purchase Plan						276	276
Issuance - majority-owned subsidiary common stock - At-The-Market Facility, net of financing charges						284	284
Issuance - majority-owned subsidiary common stock - Settlement APA-RDx - Termination Payment						713	713
Issuance - majority-owned subsidiary preferred stock						13,625	13,625
Treasury stock			(348)		348
Treasury stock, shares		188,846
Ending balance at Jun. 30, 2023	$ 2,841	$ 109	226,321	(260,783)		30,682	(830)
Ending balance, shares at Jun. 30, 2023	1,254,497	108,537,994
Beginning balance at Mar. 31, 2023	$ 2,767	$ 101	221,247	(246,172)		32,861	10,804
Beginning balance, shares at Mar. 31, 2023	1,229,887	100,596,406
Dividends declared - Series B Convertible Preferred Stock	$ 74			(74)
Dividends declared - Series B Convertible Preferred Stock, shares	24,610
Issue common stock - PAVM ATM Facility		$ 1	608				609
Issue common stock - PAVM ATM Facility, shares		1,248,750
Conversions - Senior Secured Convertible Note		$ 5	2,388				2,393
Conversions - Senior Secured Convertible Note, shares		5,192,838
Impact of subsidiary equity transactions			143			(143)
Issuance - vendor service agreement		$ 2	600			147	749
Issuance vendor service agreement, shares		1,500,000
Stock-based compensation - PAVmed Inc.			1,090				1,090
Stock-based compensation - majority-owned subsidiaries			245			1,172	1,417
Net Loss				(14,537)		(3,355)	(17,892)
Ending balance at Jun. 30, 2023	$ 2,841	$ 109	$ 226,321	$ (260,783)		$ 30,682	$ (830)
Ending balance, shares at Jun. 30, 2023	1,254,497	108,537,994